Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Barnes, Hayley ^a   Mcdonald, Julie ^b,c   Smallwood, Natasha ^d   Manser, Renée ^d,e  

^a ST VINCENT S HOSPITAL   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; OPIATE; PLACEBO; PROMETHAZINE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTERIAL GAS; BLOOD GAS ANALYSIS; CARDIOVASCULAR DISEASE; CINAHL; CLINICAL EFFECTIVENESS; CONSTIPATION; DROWSINESS; DYSPNEA; EMBASE; END TIDAL CARBON DIOXIDE TENSION; EXERCISE TEST; EXERCISE TOLERANCE; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; NAUSEA AND VOMITING; NEOPLASM; OUTCOME ASSESSMENT; OXYGEN SATURATION; PALLIATIVE THERAPY; PULSE OXIMETRY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SIX MINUTE WALK TEST; SYSTEMATIC REVIEW; TERMINAL DISEASE; WEB OF SCIENCE; PROCEDURES; TERMINAL CARE; TIME FACTOR; WALKING;

ADULT; ANALGESICS, OPIOID; DYSPNEA; EXERCISE TOLERANCE; HUMANS; MORPHINE; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERMINAL CARE; TIME FACTORS; WALKING;

EID: 84962132603     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011008.pub2     Document Type: Review

References (87)

1. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327(7414):523-8.
2. Currow DC, Plummer J, Frith P, Abernethy AP. Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine 2007;10(5):1031-6.
3. Bar-Or D, Marx JA, Good J. Breathlessness, alcohol and opiates. The New England Journal of Medicine 1982;306(22):1363-4.
4. Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine 1993;119(9):906-7.
5. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management 2008;36(1):29-38.
6. Chua T, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson P, Coats A. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology 1997;29(1):147-52.
7. Davis C, Penn K, A'Hern R, Daniels J, Slevin M. Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine 1996;10:64-5.
8. Eiser N, Denman WT, West, C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal 1991;4(8):926-31.
9. Grimbert D, Lubin O, de Monte M, Vecellio None L, Perrier M, Carré P, et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho-pulmonaire]. Revue des Maladies Respiratoires 2004;21(6 Pt 1):1091-7.
10. Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 1995;152(6):1940-5.
11. Hui D, Xu A, Frisbee-Hume S, Chisholm G, Bruera, E . Prophylactic subcutaneous fentanyl for exercise-induced breakthrough dyspnea: a preliminary double-blind, randomized controlled trial. Supportive Care in Cancer 2013;21:S191.
12. Hui D, Xu A, Frisbee-Hume S, Chisholm G, Morgado M, Reddy S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. Journal of Pain and Symptom Management 2014;47(2):209-17.
13. Jankelson D, Hosseini K, Mather LE, Seale JP, Young IH. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal 1997;10(10):2270-4.
14. Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, O'Donnell DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management 2012;43(4):706-19.
15. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in "pink puffers". British Medical Journal (Clinical Research Edition) 1983;286(6366):675-7.
16. Johnson MJ, McDonagh TA, Harkness A, McKayd SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study. European Journal of Heart Failure 2002;4(6):753-6.
17. Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax 1996;51(6):596-600.
18. Light RW, Stansbury DW, Webster JS. Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest 1996;109(4):975-81.
19. Masood AR, Reed JW, Thomas SH. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 1995;50(6):629-34.
20. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trial. Annals of Oncology 1999;10(12):1511-4.
21. Cerchietti LCA, Navigante, AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management 2007;33(3):234-6.
22. Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management 2010;39(5):820-30.
23. Noseda A, Carpiaux JP, Markstein C, Meyvaert A, de Maertelaer V. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal 1997;10(5):1079-83.
24. Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal 2012;164(2):229-35.
25. Oxberry SG, Torgerson DJ, Bland JM, Clark AL, Cleland JG, Johnson MJ. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure 2011;13(9):1006-12.
26. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1998;157(6):1877-80.
27. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest 1987;81(3):287-92.
28. Williams SG, Wright DJ, Marshall P, Reese A, Tzeng BH, Coats AJS, et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart 2003;89(9):1085-6.
29. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine 1981;305(27):1611-6.
30. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989;44(5):387-90.
31. Allard P, Lamontagne C, Bernard P, Tremblay CJ. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. Journal of Pain and Symptom Management 1999;17(4):256-65.
32. Beauford W, Saylor TT, Stansbury DW, Avalos K, Light RW. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest 1993;104(1):175-8.
33. Bruera E, Sala R, Spruyt O, Palmer L, Zhang T, Willey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. Journal of Pain and Symptom Management 2005;29(6):613-8.
34. Navigante AH, Castro M, Cerchietti L. Morphine plus midazolam versus oxygen therapy on severe dyspnea management in the last week of life in hipoxemic advanced cancer patients [Morfina más midazolan versus oxigenoterapia en el control de la disnea severa durante la última semana de vida en pacientes hipoxémicos con cáncer avanzado]. Medicina Paliativa 2003;10(1):14-9.
35. Peterson GM, Young RS, Dunne PF, Galloway JG, Parks TE. Pilot study of nebulised morphine for dyspnoea in palliative care patients. Australian Journal of Hospital Pharmacy 1996;26(5):545-7.
36. Shohrati M, Ghanei M, Harandi AA, Foroghi S, Harandi, AA . Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study. Pulmonary Medicine 2012;2012:610921.
37. Smith TJ, Coyne P, French W, Ramakrishnan V, Corrigan P. Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned. Journal of Palliative Medicine 2009;12(9):771-2.
38. Thomas J, Stambler N, Israel RJ. Methylnaltrexone, a peripheral opioid antagonist for opioid-induced constipation in advanced illness: an analysis of dyspnea in patients with chronic obstructive pulmonary disease (COPD) in two double-blind randomized trials. 18th International Congress on Palliative Care; Oct 5-8, 2010; Montreal. Journal of Palliative Care 2010;26(3):242.
39. Cuervo Pinna MA. A randomized cross-over clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. Palliative Medicine 2012;26(4):569-70.
40. Daubert E, Bolesta S. Effect of lorazepam versus morphine on quality of life in hospice patients with dyspnea and anxiety. Journal of the American Pharmacists Association 2014;54(2):e193.
41. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Amercan Journal of Respiratory and Critical Care Medicine 1999;159(1):321-40.
42. Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activate the insular cortex. NeuroReport 2000;11(10):2117-20.
43. Bausewein C, Booth S, Gysels M, Higginson IJ. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2]
44. Beach D, Schwartzstein RM. The genesis of breathlessness - what do we understand?. In: Booth S, Dudgeon D editor(s). Dyspnoea in Advanced Disease - A Guide to Clinical Management. 1st Edition. Oxford: Oxford University Press, 2006:1-18.
45. Bolser DC, Lindsey BG, Shannon R. Medullary inspiratory activity: influence of intercostal tendon organs and muscle spindle endings. Journal of Applied Physiology 1987;62(3):1046-56.
46. Bolser DC, Lindsey BG, Shannon R. Respiratory pattern changes produced by intercostal muscle/rib vibration. Journal of Applied Physiology 1988;64(6):2458-62.
47. Brannan S, Liotti M, Egan G, Shade R, Madden L, Robillard R, et al. Neuroimaging of cerebral activations and deactivations associated with hypercapnia and hunger for air. Proceedings of the National Academy of Sciences of the United States of America 2001;98(4):2029-34.
48. Chahl LA. Opioids - mechanisms of action. Australian Prescriber 1996;19:63-5.
49. Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD004769.pub2]
50. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. Journal of Pain and Symptom Management 2011;42(3):388-99.
51. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304.
52. Dudgeon J, Lertzman M. Dyspnea in the advanced cancer patient. Journal of Pain and Symptom Management 1998;16(4):212-9.
53. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
54. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. Journal of Neurophysiology 2002;88(3):1500-11.
55. Fitzgerald RS, Lahiri S. Reflex response to chemoreceptor stimulation. In: Cherniack NS, Widdicombe JG editor(s). Handbook of Physiology, Section 3: The Respiratory System, Vol. 2. Control of Breathing. Bethesda: American Physiological Society, 1986:313-62.
56. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015.
57. Guz A. Brain, breathing and breathlessness. Respiration Physiology 1997;109(3):197-204.
58. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
59. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
60. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W65-94.
61. Liotti M, Brannan S, Egan G, Shade R, Madden L, Abplanalp B, et al. Brain responses associated with consciousness of breathlessness (air hunger). Proceedings of the National Academy of Sciences of the United States of America 2001;98(4):2035-40.
62. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010;137(3):674-91.
63. Mahler DA. Opioids for refractory dyspnoea. Expert Review of Respiratory Medicine 2013;7(2):123-35.
64. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. The New England Journal of Medicine 1995;333(23):1547-53.
65. Masood AR, Thomas SH. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. British Journal of Clinical Pharmacology 1996;41(3):250-2.
66. McGavin CR, Artvinli M, Naoe H, McHardy GJR. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. British Medical Journal 1978;2(6132):241-3.
67. Nattie E. Central chemoreceptors. In: Dempsey JA, Pack AL editor(s). Regulation of Breathing. 2nd Edition. New York: Marcel Dekker, 1995:473-510.
68. Neuman A, Gunnbjörnsdottir M, Tunsäter A, Nyström L, Franklin KA, Norrman E, et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respiratory Medicine 2006;100(10):1843-9.
69. Nishino T. Dyspnoea: underlying mechanisms and treatment. British Journal of Anaesthesia 2011;106(4):463-74.
70. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515.
71. O'Donnell DE, L.M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158(5):1557-65.
72. Oxberry S, Jones L, Clark AL, Johnson MJ. Attitudes to morphine in chronic heart failure patients. Postgraduate Medical Journal 2012;88(1043):515-21.
73. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. American Journal of Respiratory and Critical Care Medicine 2012;185(4):435-52.
74. Parsons LM, Egan G, Liotti M, Brannan S, Denton D, Shade R, et al. Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air. Proceedings of the National Academy of Sciences of the United States of America 2001;98(4):2041-6.
75. Pattinson KT, Governo RJ, MacIntosh BJ, Russell EC, Corfield DR, Tracey I, et al. Opioids depress cortical centers responsible for the volitional control of respiration. Journal of Neuroscience 2009;29(25):8177-86.
76. Peiffer C, Poline JB, Thivard L, Aubier M, Samson Y. Neural substrates for the perception of acutely induced dyspnea. American Journal of Respiratory and Critical Care Medicine 2001;163(4):951-7.
77. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-- imaging a shared neuronal network. Science 2002;295(5560):1737-40.
78. Polosa R, Simidchiev A, Walters EH. Nebulised morphine for severe interstitial lung disease. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD002872]
79. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
80. Rocker G, Young J, Donahue M, Farquar M, Simpson C. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. Canadian Medical Association Journal 2012;184(9):E497-504.
81. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007354.pub2]
82. Uronis H, McCrory DC, Samsa G, Currow D, Abernethy A. Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD006429.pub2]
83. von Leupoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B, et al. Dyspnoea and pain share emotion-related brain network. NeuroImage 2009;48(1):200-6.
84. Widdicombe JG. Pulmonary and respiratory tract receptors. Journal of Experimental Biology 1982;100:42-57.
85. Wiseman R, Rowett D, Allcroft P, Abernethy A, Currow DC. Chronic refractory dyspnoea--evidence based management. Australian Family Physician 2013;42(3):137-40.
86. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sciences 2000;66(23):2221-31.
87. Jennings AL, Davies AN, Higgins JPT, Anzures-Cabrera J, Broadley KE. Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD002066]